The Board of Directors of Calliditas Therapeutics AB (publ) (“Calliditas”) has resolved on a directed new issue of shares, whereby the company will raise proceeds of approximately SEK 210 million, before issue costs.
The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank and Zonda Partners.
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts.
Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Edin Agic.